Spectrum Pharmaceuticals, Inc. SPPI
Jul 31, 2023, 3:56 PM EDT
52-week range unavailable
- Market cap
- 210.38M
- Revenue (ttm)
- 25.73M
- Profit margin
- -252.50%
- Shares out
- 205.25M
- Forward P/E
- 7.34
- Volume
- 4.85M
- Open
- 1.02
- Previous close
- 1.03
- Day's range
- 0.9716 – 1.06
- Beta
- 2.14
- Analysts
- Hold
- Price target
- 1.26 (+22.9%)
- Earnings date
- Aug 10, 2023
2Y -1.15 (-52.75%)
Key statistics
- Enterprise value
- 168.20M
- PEG ratio
- 0.00
- Price / sales
- 7.62
- Price / book
- 7.23
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -78.77M
- Total cash
- 56.14M
- Total debt
- 30.47M
- Return on equity
- -165.02%
- Short % of float
- 1.61%
- 50-day average
- 1.08
- 200-day average
- 0.71255
Analyst view
Consensus: hold
- Target (low)
- 1.14
- Target (mean)
- 1.26
- Target (high)
- 1.50
- Strong buy2
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 10, 2023
Expected Aug 10, 2023. Consensus EPS estimate -0.03.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 10, 2023 | Jun 1, 2023 | -0.04 | — | — | — |
| May 9, 2023 | Mar 1, 2023 | -0.05 | — | — | — |
| Mar 22, 2023 | Dec 1, 2022 | -0.09 | — | — | — |
| Nov 10, 2022 | Sep 1, 2022 | -0.15 | — | — | — |
| Aug 11, 2022 | Jun 1, 2022 | -0.16 | — | — | — |
| May 12, 2022 | Mar 1, 2022 | -0.18 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 26, 2023 | HC Wainwright & Co. | reit | Neutral | Neutral |
| May 15, 2023 | Jefferies | down | Buy | Hold |
| Apr 26, 2023 | HC Wainwright & Co. | down | Buy | Neutral |
| Apr 26, 2023 | JMP Securities | down | Market Outperform | Market Perform |
| Feb 6, 2023 | JMP Securities | reit | — | Market Outperform |
| Feb 3, 2023 | Cantor Fitzgerald | main | — | Neutral |
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- sppirx.com
News
Dow Dips Over 300 Points; McDonald's Beats Q1 Expectations 
Why Chicken Soup For The Soul Entertainment Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket 
Earnings Scheduled For March 22, 2023 
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga's Top Ratings Upgrades, Downgrades For November 16, 2022
- Earnings Scheduled For November 10, 2022
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know 
Stocks That Hit 52-Week Lows On Wednesday - Stocks That Hit 52-Week Lows On Tuesday
Why NanoVibronix Shares Surged Over 25%; Here Are 82 Biggest Movers From Friday
Your note
Sign in to keep a note on SPPI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ASHTON WILLIAM L | Director | Stock Award(Grant) | Aug 30, 2022 | 67,660 |
| BRADRICK BRITTANY K. | Director | Stock Award(Grant) | Aug 30, 2022 | 27,380 |
| BRENNAN NORA | Chief Financial Officer | Sale | May 25, 2023 | 567,828 |
| FISCHER SETH H Z | Director | Stock Award(Grant) | Aug 30, 2022 | 54,066 |
| LEBEL FRANCOIS | Officer | Sale | Jun 22, 2022 | 652,016 |
| LIM JUHYUN | Director | Stock Award(Grant) | Aug 30, 2022 | 29,759 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 8.14% | 16,700,000 | 15.94M | Mar 30, 2023 |
| Vanguard Group, Inc. (The) | 4.28% | 8,777,670 | 8.38M | Mar 30, 2023 |
| Acadian Asset Management. LLC | 1.81% | 3,712,411 | 3.54M | Mar 30, 2023 |
| Blackrock Inc. | 1.68% | 3,448,478 | 3.29M | Mar 30, 2023 |
| Geode Capital Management, LLC | 0.86% | 1,757,437 | 1.68M | Mar 30, 2023 |
| Morgan Stanley | 0.56% | 1,146,119 | 1.09M | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.61% | 5,348,837 | 5.11M | Dec 30, 2022 |
| Vanguard Extended Market Index Fund | 1.11% | 2,285,849 | 2.18M | Dec 30, 2022 |
| Fidelity Extended Market Index Fund | 0.44% | 895,733 | 855.16K | Feb 27, 2023 |
| Vanguard Variable Insurance Fund-Small Company Growth | 0.23% | 475,988 | 454.43K | Dec 30, 2022 |
| Fidelity Total Market Index Fund | 0.16% | 326,441 | 311.65K | Feb 27, 2023 |
| Fidelity Series Total Market Index Fund | 0.10% | 210,764 | 201.22K | Feb 27, 2023 |